Archive for the ‘Genetic testing’ Category

NEW PROSTATE CANCER INFOLINK: The US Food and Drug Administration is warning companies offering genetic tests for diseases – including prostate cancer – that their claims can’t be backed up by research data.

Mike Scott says the prostate cancer ones are, as yet, not particularly useful, and he sets out criteria for companies to meet as more tests are developed and marketed over the next five years. READ MORE>

Read Full Post »

URO TODAY: Urine samples that show higher levels of PCA3 – a prostate-specific messenger gene – could be an accurate indication of prostate cancer, Italian researchers report. READ MORE>

Our results indicate that the PCA3 score is a valid tool for prostate cancer detection and its role in making better biopsy decisions.

This marker [helps] to discriminate patients who have to undergo biopsy from patients who only need be actively surveilled: Quantitative PCA3 score is correlated with the probability of a positive result at biopsy.

Read Full Post »

URO TODAY: Mapping gene alterations in “intermediate risk” prostate cancer patients may be an effective way of deciding what treatment to apply. READ MORE>

The use of high-resolution comparative genomic hybridization for fine-mapping of deletions and amplifications in pre-radiotherapy prostate cancer biopsies is feasible.

Genetic alterations may delineate localised prostate cancer from systemic disease and be used as a predictive factor in that patients would be individually triaged to local (surgery versus radiotherapy) and/or adjuvant (adjuvant androgen ablation or post-operative radiotherapy) therapies in a prospective fashion to improve outcome.

Read Full Post »

URO TODAY:  Activation of the ERG gene, by combining with other genes, is one of the key genetic defects in prostate cancer and US researchers have developed a highly accurate test for it. READ MORE>

Read Full Post »

URO TODAY: Researchers have investigated associations between 29 single nucleotide polymorphisms (SNP) and biochemical recurrence, castration-resistant metastasis, and prostate cancer-specific survival, and found the SNPs are a clue to outcomes. READ MORE>

Read Full Post »

URO TODAY: Testing for prostate cancer Gene 3 in urine from men under active surveillance is not on its own a useful predictor of disease progression. READ MORE>

Read Full Post »

URO TODAY: Two prostate cancer genome-wide scans in populations of European ancestry have identified several genetic variants that are strongly associated with prostate cancer risk. READ MORE>

Read Full Post »

Older Posts »


Get every new post delivered to your Inbox.

Join 26 other followers